A phase I, open, multiple dose, dose escalation and expansion study to evaluate the safety, tolerability, and pharmacokinetics of KN035 (anti-PD-L1 antibody) administered in subcutaneous injection as a single agent to Chinese subjects with advanced solid tumors.

Xu, Jianming; Qin, Shukui; Zhang, Yun; Zhang, Yaoyue; Jia, Ru; Liu, Rongrui; Wang, Yan; Zhang, Gairong; Zhao, Chuanhua; Lu, Ni; Ma, Xiaoyu; He, Yue; Yuan, Liwei; Lin, Yihui; Xu, Wenlian; Wang, Xiaoxiao; Wang, Pilin; Xu, Ting; Dong, RuiPing; Gong, John

doi:10.1200/JCO.2018.36.15_suppl.e15138

免费注册

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

A phase I, open, multiple dose, dose escalation and expansion study to evaluate the safety, tolerability, and pharmacokinetics of KN035 (anti-PD-L1 antibody) administered in subcutaneous injection as a single agent to Chinese subjects with advanced solid tumors.

作者：Xu, Jianming; Qin, Shukui; Zhang, Yun; Zhang, Yaoyue; Jia, Ru; Liu, Rongrui; Wang, Yan; Zhang, Gairong; Zhao, Chuanhua; Lu, Ni; Ma, Xiaoyu; He, Yue; Yuan, Liwei; Lin, Yihui; Xu, Wenlian; Wang, Xiaoxiao; Wang, Pilin; Xu, Ting; Dong, RuiPing; Gong, John

DOI：10.1200/JCO.2018.36.15_suppl.e15138